Skip to main content
Use this button to show the site search bar.
Clinical Guidelines Platform
Clinical Guidelines Platform
Search for toolkits, guidelines and other information:
Search
Menu
Contact and Feedback
About
Notifications
Home
Back
Central Nervous System
Musculoskeletal
Musculoskeletal
Aqueous Phenol (use of 6%) in unlicensed indications in pathological muscle hypertonia
Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome, medicines that may affect patients
Protocol for use of Botulinum toxin A in Unlicensed Indications in Pathological Muscle Hypertonia
Post Stroke Spasticity Service Use of Botulinum Toxin A
Central Nervous System
Addictions
Epilepsy
Head Injuries
Mental Health
Migraine
Motor Neuron Disease
Multiple Sclerosis
Musculoskeletal
Aqueous Phenol (use of 6%) in unlicensed indications in pathological muscle hypertonia
Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome, medicines that may affect patients
Protocol for use of Botulinum toxin A in Unlicensed Indications in Pathological Muscle Hypertonia
Post Stroke Spasticity Service Use of Botulinum Toxin A
Other related guidelines
Paediatrics
Parkinson's Disease
Back to the top
